未登录

M

Mats Någård

AstraZeneca

H指数:17

被引数:1,160

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2025-12-010

OAAI

Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration

抑制OATP1B1/3而非UGT1A1可能是阿扎那韦给药后胆红素升高的主要原因

Clinical Pharmacology & Therapeutics

IF5.5

2024-12-140

OAAI

Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19

在大流行期间加速治疗药物的开发: 长效抗体组合AZD7442 (tixagevimab/cilgavimab) 在预防和治疗新型冠状病毒肺炎中的群体药代动力学

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2024-05-023

OAAI

Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model-informed drug development case study

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-12-041

OAAI

A systematic review of pregnancy-related clinical intervention of drug regimens due to pharmacokinetic reasons

因药代动力学原因对妊娠相关用药方案进行临床干预的系统评价

FRONTIERS IN MEDICINE

IF3

2023-11-293

OAAI

Understanding Statin-Roxadustat Drug-Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-07-136

OAAI

A Phase 1, open-label, crossover study evaluating the effect of a single dose of sodium zirconium cyclosilicate on the pharmacokinetics of tacrolimus and cyclosporin

CLINICAL KIDNEY JOURNAL

IF4.6

2022-09-132

OAAI

Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-01-239

OA

Evaluation of potential drug interactions with sodium zirconium cyclosilicate: a single-center, open-label, one sequence crossover study in healthy adults

CLINICAL KIDNEY JOURNAL

IF4.6

2020-12-293

OAAI

Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study

CLINICAL KIDNEY JOURNAL

IF4.6

2020-12-1311

OAAI

Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19 and CYP3A4 in patients with advanced solid tumors

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Adavosertib (AZD1775) does not prolong QT interval in patients with advanced solid tumors: A Phase I open-label study Lin

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2019-03-1430

PREAI

Prediction of human lung PK for AZD7624, an inhaled P38 inhibitor for the treatment of COPD

EUROPEAN RESPIRATORY JOURNAL

IF21

2015-10-300

PRE

Transient Lower Esophageal Sphincter Relaxation Pharmacokinetic-Pharmacodynamic Modeling: Count Model and Repeated Time-To-Event Model

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2011-12-0117

PREAI

Dissociative recombination of H+(H2O)3 and D+(D2O)3 water cluster ions with electrons:: Cross sections and branching ratios

JOURNAL OF CHEMICAL PHYSICS

IF3.1

2007-11-1518

PREAI

Dissociative recombination of ammonia clusters studied by storage ring experiments

JOURNAL OF CHEMICAL PHYSICS

IF3.1

2006-11-1612

PREAI

Rapid screening of pKa values of pharmaceuticals by pressure-assisted capillary electrophoresis combined with short-end injection

JOURNAL OF CHROMATOGRAPHY A

IF4

2002-12-0193

PREAI